Vertex announces european medicines agency validation for marketing authorization application extension for kaftrio® in combination with ivacaftor to include people with cystic fibrosis and responsive rare mutations

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) today announced that the european medicines agency (ema) has validated a type ii variation application to the marketing authorization for kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor. the application is for expansion of the approved indication for kaftrio® in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis (cf) ages 2 and above who have a mutation in the cystic fibro.
VRTX Ratings Summary
VRTX Quant Ranking